Pasithea Therapeutics (KTTA) Earnings Date & Reports

Key Takeaways

• Pasithea Therapeutics is expected to report its third-quarter 2026 results around November 12, 2026, after the market close.
• Wall Street consensus projects a net loss of approximately $0.21 per share for the quarter, versus a reported loss of $0.16 per share in the prior quarter.
• As a clinical-stage biotechnology company, Pasithea generates minimal revenue, so investors will focus on research and development spending, cash burn, and clinical updates rather than top-line growth.
• Key watch items include progress on PAS-004, its lead MEK inhibitor candidate, and PAS-003, its amyotrophic lateral sclerosis (ALS) program.
• The company's recent earnings history has been volatile, with a narrower-than-expected loss in Q1 2026 and a wider-than-expected loss in Q4 2025.
• For more information about the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Investors looking for automated market insights can also explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

Pasithea Therapeutics Corp. (KTTA) is a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, RASopathies, and certain cancers. Because it has no approved products yet, its quarterly results are driven primarily by operating expenses rather than revenue. For investors, this report is less about profitability and more about execution: how efficiently management is deploying capital, whether cash reserves remain sufficient, and whether clinical programs are advancing on schedule. Prior quarters have shown meaningful swings in the company's loss per share, reflecting the lumpy nature of early-stage development spending. With the stock trading at a relatively low share price, any signal on pipeline progress or funding runway could move sentiment quickly.

Earnings Expectations

Analysts expect Pasithea Therapeutics to report a loss of roughly $0.21 per share for its third quarter ended September 30, 2026, according to consensus estimates. Revenue expectations remain minimal—in the range of $0.2 million or less—consistent with a company that has historically reported little to no product revenue.

For context, the company reported a loss of $0.16 per share in Q2 2026, matching the consensus estimate of -$0.16. In Q1 2026, it delivered a narrower-than-expected loss of $0.12 per share against an estimate of -$0.45, while Q4 2025 saw a much wider-than-expected loss of $0.89 per share. This uneven history underscores the difficulty of forecasting a development-stage biotech's bottom line, where one-time charges and shifting R&D (research and development) timelines can create large quarter-to-quarter swings.

Beyond the headline loss, investors will be watching research and development expenses, general and administrative costs, and the company's cash position, which determine how long it can operate before needing additional funding.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following small-cap biotech names like KTTA, the AI Screener can surface comparable companies and emerging setups worth monitoring.

Market Reaction and Investor Sentiment

Sentiment heading into this report reflects the broader challenges facing clinical-stage biotechs: limited revenue, meaningful cash burn, and binary risk tied to clinical outcomes. Pasithea's shares have traded in a relatively wide range over the past year, and its earnings reactions have been inconsistent. A loss that is narrower than the -$0.21 consensus estimate—especially if paired with commentary showing disciplined spending—could be viewed positively. Conversely, an unexpected widening of the loss or signs of accelerating cash burn could pressure the stock, given the company's modest market capitalization. Investors are also sensitive to any financing announcements, as dilution risk remains a key concern for pre-revenue biotech companies.

Forward Outlook and Key Factors to Monitor

Following this earnings release, investors should watch several forward-looking signals. First, guidance or commentary on the company's cash runway—the estimated length of time it can fund operations with existing capital—will be critical. A shorter-than-expected runway could foreshadow a future equity raise, which may dilute existing shareholders.

Second, any updates on PAS-004, a next-generation MEK (mitogen-activated protein kinase) inhibitor being developed for RASopathies and MAPK pathway-driven tumors, and PAS-003, the ALS candidate, will matter more than the quarterly loss itself. Clinical-stage companies are ultimately valued on the promise of their pipeline, so trial enrollment progress, data timelines, and regulatory interactions are key catalysts.

Third, monitor the trajectory of research and development expenses. Investors want to see spending aligned with meaningful clinical milestones rather than rising without corresponding progress. Finally, broader sector dynamics—including funding availability for small-cap biotechs and regulatory sentiment—may influence how the market interprets this report. As always, these observations are informational and should not be taken as investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations